BACKGROUND AND PURPOSE: The P2X(7) receptor exhibits complex pharmacological properties. In this study, binding of a [(3)H]-labelled P2X(7) receptor antagonist to human P2X(7) receptors has been examined to further understand ligand interactions with this receptor. EXPERIMENTAL APPROACH: The P2X(7) receptor antagonist, N-[2-({2-[(2-hydroxyethyl)amino]ethyl}amino)-5-quinolinyl]-2-tricyclo[3.3.1.1(3,7)]dec-1-ylacetamide (compound-17), was radiolabelled with tritium and binding studies were performed using membranes prepared from U-2 OS or HEK293 cells expressing human recombinant P2X(7) receptors. KEY RESULTS: Binding of [(3)H]-compound-17 was higher in membranes prepared from cells expressing P2X(7) receptors than from control cells and was inhibited by ATP suggesting labelled sites represented human P2X(7) receptors. Binding was reversible, saturable and modulated by P2X(7) receptor ligands (Brilliant Blue G, KN62, ATP, decavanadate). Furthermore, ATP potency was reduced in the presence of divalent cations or NaCl. Radioligand binding exhibited both positive and negative cooperativity. Positive cooperativity was evident from bell shaped Scatchard plots, reduction in radioligand dissociation rate by unlabelled compound-17 and enhancement of radioligand binding by KN62 and unlabelled compound-17. ATP and decavanadate inhibited binding in a negative cooperative manner as they enhanced radioligand dissociation. CONCLUSIONS: These data demonstrate that human P2X(7) receptors can be directly labelled and provide novel insights into receptor function. The positive cooperativity observed suggests that binding of compound-17 to one subunit in the P2X(7) receptor complex enhances subsequent binding to other P2X(7) subunits in the same complex. The negative cooperative effects of ATP suggest that ATP and compound-17 bind at separate, interacting, sites on the P2X(7) receptor.
BACKGROUND AND PURPOSE: The P2X(7) receptor exhibits complex pharmacological properties. In this study, binding of a [(3)H]-labelled P2X(7) receptor antagonist to human P2X(7) receptors has been examined to further understand ligand interactions with this receptor. EXPERIMENTAL APPROACH: The P2X(7) receptor antagonist, N-[2-({2-[(2-hydroxyethyl)amino]ethyl}amino)-5-quinolinyl]-2-tricyclo[3.3.1.1(3,7)]dec-1-ylacetamide (compound-17), was radiolabelled with tritium and binding studies were performed using membranes prepared from U-2 OS or HEK293 cells expressing human recombinant P2X(7) receptors. KEY RESULTS: Binding of [(3)H]-compound-17 was higher in membranes prepared from cells expressing P2X(7) receptors than from control cells and was inhibited by ATP suggesting labelled sites represented human P2X(7) receptors. Binding was reversible, saturable and modulated by P2X(7) receptor ligands (Brilliant Blue G, KN62, ATP, decavanadate). Furthermore, ATP potency was reduced in the presence of divalent cations or NaCl. Radioligand binding exhibited both positive and negative cooperativity. Positive cooperativity was evident from bell shaped Scatchard plots, reduction in radioligand dissociation rate by unlabelled compound-17 and enhancement of radioligand binding by KN62 and unlabelled compound-17. ATP and decavanadate inhibited binding in a negative cooperative manner as they enhanced radioligand dissociation. CONCLUSIONS: These data demonstrate that human P2X(7) receptors can be directly labelled and provide novel insights into receptor function. The positive cooperativity observed suggests that binding of compound-17 to one subunit in the P2X(7) receptor complex enhances subsequent binding to other P2X(7) subunits in the same complex. The negative cooperative effects of ATP suggest that ATP and compound-17 bind at separate, interacting, sites on the P2X(7) receptor.
Authors: William C Clay; J Patrick Condreay; Linda B Moore; Susan L Weaver; Michael A Watson; Thomas A Kost; Jennifer J Lorenz Journal: Assay Drug Dev Technol Date: 2003-12 Impact factor: 1.738
Authors: Shane M Wilkinson; Hendra Gunosewoyo; Melissa L Barron; Aurelie Boucher; Michelle McDonnell; Peter Turner; Daniel E Morrison; Maxwell R Bennett; Iain S McGregor; Louis M Rendina; Michael Kassiou Journal: ACS Chem Neurosci Date: 2014-04-03 Impact factor: 4.418
Authors: E Fonfria; W C Clay; D S Levy; J A Goodwin; S Roman; G D Smith; J P Condreay; A D Michel Journal: Br J Pharmacol Date: 2007-11-26 Impact factor: 8.739
Authors: Gevdeep Bhabra; Aman Sood; Brenton Fisher; Laura Cartwright; Margaret Saunders; William Howard Evans; Annmarie Surprenant; Gloria Lopez-Castejon; Stephen Mann; Sean A Davis; Lauren A Hails; Eileen Ingham; Paul Verkade; Jon Lane; Kate Heesom; Roger Newson; Charles Patrick Case Journal: Nat Nanotechnol Date: 2009-12 Impact factor: 39.213
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: R Bertelli; M Bodria; M Nobile; S Alloisio; R Barbieri; G Montobbio; P Patrone; G M Ghiggeri Journal: Clin Exp Immunol Date: 2011-07-15 Impact factor: 4.330
Authors: Loren C Denlinger; David M Manthei; Max A Seibold; Kwangmi Ahn; Eugene Bleecker; Homer A Boushey; William J Calhoun; Mario Castro; Vernon M Chinchili; John V Fahy; Greg A Hawkins; Nicolina Icitovic; Elliot Israel; Nizar N Jarjour; Tonya King; Monica Kraft; Stephen C Lazarus; Erik Lehman; Richard J Martin; Deborah A Meyers; Stephen P Peters; Dagna Sheerar; Lei Shi; E Rand Sutherland; Stanley J Szefler; Michael E Wechsler; Christine A Sorkness; Robert F Lemanske Journal: Am J Respir Crit Care Med Date: 2012-11-09 Impact factor: 21.405
Authors: A D Michel; W C Clay; S W Ng; S Roman; K Thompson; J P Condreay; M Hall; J Holbrook; D Livermore; S Senger Journal: Br J Pharmacol Date: 2008-07-28 Impact factor: 8.739